Baxter has three manufacturing facilities in Puerto Rico, all of which are operating on limited manufacturing capacity. As a result, many U.S. hospitals are experiencing shortages of Baxter’s IV products.
Baxter CEO José Almeida told analysts the company should achieve normal inventory levels for affected products — and see little financial impact from the supply chain disruptions — by the first quarter of 2018, according to Reuters.
More articles on supply chain:
FDA OKs expanded use for Alexion’s ultra-rare disease drug
Survey: 61% of patient advocacy groups have favorable view of devicemakers
Hospitals grapple with medical supply shortages in wake of Hurricane Maria: 4 things to know
